Surmodics | SRDX - Cash And Equivalent


Surmodics reported $36.11M in Cash and Equivalent for its fiscal quarter ending in September of 2024.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Align Technology USD 1.06B 35.07M Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
Artivion USD 55.76M 9.14M Mar/2026
Baxter International USD 2.02B 51M Mar/2026
Boston Scientific USD 1.45B 512M Mar/2026
EDAP TMS EUR 29.84M 4.35M Dec/2024
Edwards Lifesciences USD 2.4B 538M Mar/2026
Haemonetics USD 245.44M 117.93M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Merit Medical Systems USD 488.08M 41.68M Mar/2026
Mesa Laboratories USD 28.98M 8.55M Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Option Care Health USD 177.32M 55.3M Mar/2026
Stryker USD 2.88B 1.13B Mar/2026
Surmodics USD 36.11M 11.81M Sep/2024
Trinity Biotech USD 1.34M 3.83M Sep/2025